ClinicalTrials.gg
CompletedNCT02716857Updated Mar 5, 2018

Efficacy and Safety of Egalet-002 in Patients With Moderate-to-Severe Chronic Low Back Pain

A Phase 3 interventional study of Oxycodone extended-release and Placebo of oxycodone extended-release in Moderate-to-severe Chronic Low Back Pain, sponsored by Egalet Ltd. Completed at 74 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-03-05.

Sponsored by Egalet Ltd · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
549
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 711 studies in Low Back Pain with a site in United States — 99 open to participants now, 125 under way, 3 of them phase 3. Low Back Pain · United States.

Enrollment
43rd of 623
549 · median 79
Started
2016
with 24 others
Phase 3
62 of 711
1 open now
Registered
339th of 711
by date

Among the 711 studies in Low Back Pain with a site in United States, this one is the 43rd largest by enrollment of the 623 interventional ones that give a count, is one of 25 that started in 2016, is one of 62 in phase 3, and was the 339th registered.

Low Back Pain

2,926 studies on the registry are indexed under Low Back Pain; 579 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

99 of the 711 studies in Low Back Pain with a site in United States are open now. Recruiting first, the newest first:

94 more — sign in →

All 99 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 711 studies in Low Back Pain with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine the analgesic efficacy of Egalet-002 twice daily (BID) in patients with moderate-to-severe chronic low back pain

03

Conditions studied

  • Moderate-to-severe Chronic Low Back Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is an English-speaking man or woman between 18 and 75 years of age who has given written .
  • Has a clinical diagnosis of moderate-to-severe low back pain (Quebec Task Force Class 1 to 3) for ≥6 months.
  • Is opioid naïve (ie, taking \<20 mg oxycodone/day or opioid equivalent) or is opioid experienced (ie, taking a dose between 20 and 240 mg [inclusive] oxycodone/day or opioid equivalent) for management of moderate-to-severe CLBP at least 14 days prior to screening and will, in the opinion of the investigator, continue to require opioid therapy (between 20 and 240 mg oxycodone/day, inclusive) for management of moderate-to-severe CLBP for the duration of the study.
  • Has stable health, as determined by the investigator,
  • If female, the patient is currently not pregnant, not breast-feeding, nor attempting to become pregnant (for 30 days before screening and throughout the duration of the study), or is of non-

Exclusion criteria

Exclusion Criteria:

  • Has cancer-related pain.
  • Has a history of receiving >240 mg oxycodone (or equivalent) daily within 30 days before screening.
  • Has a lumbar spinal infusion pump in use or used within 6 months before screening.
  • Has clinically unstable cardiac disease (including atrial fibrillation, symptomatic bradycardia, unstable congestive heart failure, or active myocardial ischemia)
  • Has positive urine drug toxicity screen for illegal or non-prescribed drugs
  • Has current (or history of within the last 5 years prior to screening) drug dependence or substance abuse disorder according to , 5th Edition, Text Revision criteria (excluding nicotine).
  • Has positive result for cannabinoids (even if legally prescribed).
  • Has a history of attempted suicide.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Investigator)
Enrollment
549 participants (actual)

Study arms

  • Experimental
    Oxycodone extended-release

    Egalet ADER oxycodone tablet

    Drug: Oxycodone extended-release

  • Placebo comparator
    Placebo of Oxycodone extended-release

    Egalet ADER oxycodone placebo tablet

    Drug: Placebo of oxycodone extended-release

Interventions

06

What researchers measure

Primary outcomes

  1. Measure of Average Pain Intensity past 24 hours, as measured by a 0-10 NPRS using eDiary collection daily at bedtime.

    Time frame: 16 weeks

Secondary outcomes

  1. Efficacy: daily (past 24 hours) worst pain intensity score (WPI)

    Time frame: 16 Weeks

  2. Safety: Incidence of TEAEs, including those leading to treatment withdrawal, and/or abnormal physical examination findings, vital signs measurements, ECGs, and clinical laboratory test results, related to treatment

    Time frame: 16 weeks

07

Study locations

74 sites
  • Site 207
    Birmingham, Alabama 35209, United States
  • Site 202
    Mobile, Alabama 36608, United States
  • Site 253
    Phoenix, Arizona 85018, United States
  • Site 260
    Phoenix, Arizona 85018, United States
  • Site 268
    Phoenix, Arizona 85029, United States
  • Site 282
    Tucson, Arizona 85704, United States
  • Site 217
    Anaheim, California 92801, United States
  • Site 280
    Anaheim, California 92804, United States
  • Site 220
    La Mesa, California 91942, United States
  • Site 235
    Laguna Hills, California 92637, United States
  • Site 215
    Long Beach, California 90806, United States
  • Site 238
    Los Gatos, California 95032, United States
  • Site 262
    Napa, California 94558, United States
  • Site 201
    Oakland, California 94607, United States
  • Site 225
    Sacramento, California 95831, United States
  • Site 231
    San Diego, California 92105, United States
  • Site 237
    San Diego, California 92120, United States
  • Site 221
    Wildomar, California 92595, United States
  • Site 248
    Boulder, Colorado 80301, United States
  • Site 228
    Bradenton, Florida 34205, United States
  • Site 214
    Clearwater, Florida 33765, United States
  • Site 270
    Gainesville, Florida 32607, United States
  • Site 269
    Inverness, Florida 34452, United States
  • Site 227
    Jupiter, Florida 33458, United States
  • SIte 204
    Lake Worth, Florida 33462, United States
  • Site 211
    Miami Beach, Florida 33140, United States
  • Site 229
    Miami Beach, Florida 33140, United States
  • Site 278
    Plantation, Florida 33317, United States
  • Site 232
    Port Orange, Florida 32129, United States
  • Site 264
    Sarasota, Florida 34232, United States
  • Site 271
    Winter Park, Florida 32789, United States
  • Site 223
    Atlanta, Georgia 30309, United States
  • Site 212
    Marietta, Georgia 30060, United States
  • Site 245
    Boise, Idaho 83713, United States
  • Site 255
    Chicago, Illinois 60614, United States
  • Site 222
    Evansville, Indiana 47714, United States
  • SIte 236
    West Des Moines, Iowa 50265, United States
  • Site 277
    Overland Park, Kansas 66210, United States
  • Site 206
    New Orleans, Louisiana 70115, United States
  • Site 224
    Shreveport, Louisiana 71105, United States
  • Site 249
    Pikesville, Maryland 21208, United States
  • Site 226
    Boston, Massachusetts 02135, United States
  • Site 254
    New Bedford, Massachusetts 02740, United States
  • Site 210
    Bay City, Michigan 48706, United States
  • Site 244
    Jackson, Mississippi 39202, United States
  • Site 234
    Hazelwood, Missouri 63042, United States
  • Site 265
    Omaha, Nebraska 68114, United States
  • Site 266
    Princeton, New Jersey 08540, United States
  • Site 267
    Somerset, New Jersey 08873, United States
  • Site 252
    Albuquerque, New Mexico 87102, United States
  • Site 261
    Kew Gardens, New York 11415, United States
  • Site 243
    New York, New York 10019, United States
  • Site 233
    Rochester, New York 14618, United States
  • Site 208
    Williamsville, New York 14221, United States
  • Site 203
    Charlotte, North Carolina 28209, United States
  • Site 213
    Winston-Salem, North Carolina 27103, United States
  • Site 242
    Winston-Salem, North Carolina 27103, United States
  • Site 276
    Columbus, Ohio 43210, United States
  • Site 209
    Franklin, Ohio 45005, United States
  • Site 259
    Kettering, Ohio 45429, United States
  • Site 240
    Toledo, Ohio 43623, United States
  • Site 239
    Oklahoma City, Oklahoma 73119, United States
  • Site 279
    Duncansville, Pennsylvania 16635, United States
  • Site 256
    Jenkintown, Pennsylvania 19046, United States
  • Site 258
    Lansdale, Pennsylvania 19446, United States
  • Site 205
    Charleston, South Carolina 29406, United States
  • Site 247
    Greenville, South Carolina 29601, United States
  • Site 251
    Spartanburg, South Carolina 29303, United States
  • Site 218
    Austin, Texas 78704, United States
  • Site 263
    Hurst, Texas 76054, United States
  • Site 219
    Richardson, Texas 75080, United States
  • Site 275
    San Antonio, Texas 78207, United States
  • Site 241
    Everett, Washington 98201, United States
  • Site 257
    Spokane, Washington 99202, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2016, a primary completion of Aug 2017 and a completion of Nov 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2016
First posted
Mar 23, 2016
Start
Mar 2016
Primary completionActual
Aug 2017
CompletionActual
Nov 2017
Last update
Mar 5, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02716857
Lead sponsor
Egalet Ltd
Responsible party
Sponsor
First posted
Mar 23, 2016
Start date
Mar 2016
Primary completion
Aug 2017
Completion
Nov 2017
Last update
Mar 5, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxycodone

Start the discussion